(MENAFN- EIN Presswire)
Huntington's Disease Treatment Market
Surge in demand for advanced drug types for controlling symptoms associated with Huntington's drive growth of the Global Huntington's disease treatment market.
The major players profiled in the Huntington's treatment market are Annexon Biosciences, Bausch Health Companies Inc, Dr's Laboratories Ltd,” - Allied Market Research
WILMINGTON, DELAWARE , UNITED STATES, April 5, 2024 /EINPresswire / -- Allied Market Research published a report, titled, "Huntington's Disease Treatment Market by Drug type (Approved drugs, Offlabel drugs), by Age (Below 50 years, Above 50 years), by Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031" According to the report, the global Huntington's disease treatment industry was estimated at $315.2 million in 2021, and is anticipated to hit $707.5 million by 2031, registering a CAGR of 8.4% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chains, competitive scenarios, and regional landscapes.
The global Huntington's disease treatment market is witnessing growth driven by a growing population and an increased demand for advanced drug types aimed at managing associated symptoms. However, the market faces obstacles due to complications associated with treatment. Nevertheless, the rising demand for advanced treatments presents lucrative opportunities for industry expansion.
In 2021, the approved drugs segment dominated the global Huntington's disease treatment market, accounting for over four-fifths of the market share, and it is projected to maintain its leadership position through 2031. Moreover, this segment is anticipated to experience the highest compound annual growth rate (CAGR) of 8.5% from 2022 to 2031. This growth can be attributed to the increasing demand for effective treatments and the rapid development of other disease-modifying drugs.
Request Sample Copy of Report
In 2021, the age group below 50 years captured over half of the global market share in Huntington's disease treatment, a trend projected to persist through 2031. This segment is forecasted to demonstrate the fastest compound annual growth rate (CAGR) of 8.6% from 2022 to 2031. The higher prevalence of the disease in this age bracket primarily drives this growth trajectory.
In 2021, North America commanded a significant portion of the global Huntington's disease treatment market, accounting for more than two-fifths of the total share. This dominance is credited to advancements in treatment technology for Huntington's disease and the substantial presence of key industry players within the region. Meanwhile, the Asia-Pacific region is anticipated to witness the fastest compound annual growth rate (CAGR) of 9.2% during the forecast period. This growth is propelled by a rising patient population, ongoing development of healthcare infrastructure, and increased investment initiatives in the region.
Key findings of the study
. By drug type, the approved drugs segment was the highest contributor to the market in 2021.
. By age, the below 50 years segment was the highest contributor to the market in 2021.
. Depending on distribution channel, the drug store & retail pharmacies segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.
. Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
For Purchase Inquiry-
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the huntington's disease treatment market analysis from 2021 to 2031 to identify the prevailing huntington's disease treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the huntington's disease treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global huntington's disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key players in the industry-
Bausch Health Companies Inc.
Eli Lilly And Company
Hikma Pharmaceuticals PLC
Lupin
Medesis pharma SA
Annexon Biosciences
Vaccinex, Inc.
Mitochon Pharmaceuticals
Neurocrine bioscience Inc.
Dr's Laboratories Ltd
Novartis
PTC Therapeutics, Inc.
SOM Biotech
Sun Pharmaceuticals
Teva Pharmaceuticals Industries Ltd.
UniQure
David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
MENAFN05042024003118003196ID1108062817
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.